U.S. markets closed

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4600+0.0400 (+2.82%)
At close: 4:00PM EDT
Sign in to post a message.
  • c
    christian
    Hoping for partnership news this week or next week
  • D
    David
    This stock can remain depressed for a long time or it can bounce like a cat with partnership news, Clarus news, and NASH news. Particularly if we get 3/3. Not sure what happens if we get 1/3 or 2/3. So we can say that the 95% confidence interval for the price of the stock this year is $0.5-$10 with outcomes in the $1.0-$4 range being the likelier outcomes. You have to love the dispersion of possible outcomes. It is a bit maddening to see such wide dispersion.
  • E
    Edmund
    Are we socializing medicine tomorrow, what in the world is going on in small biotech??? I know Dogecoin is attractive right now, I had a chance to but at .03 but chose to look the other way, but can someone explain why the biotech are getting hammered when the russell and bio indexes, albeit not by much, are up today?
  • j
    jeff
    I think we r now back in any day now mode. Clearly most of u know 130 million market cap given this companies pipeline is grossly undervalued.
  • C
    Chips
    $LPCN So Monday we have the "meeting in good faith to find a solution" I wouldn't hold my breath on that but we may finally end up with a court date!
    Bullish
  • j
    jeff
    Big week ahead
  • I
    IAN
    Prediction: If there is positive NASH news, the company will add some of those shares that are to be issued. This is good news for LPCN. It is bad news for those hoping for a quick pop. I think the term 'long-term' - now means 2 months rather than 3-5 years. I am extremely comfortable with my investment in LPCN. A lot of the 'longs - pumpers' here - do not seem to be as comfortable. They just want to move on to the next thing. OH - BTW - if you think I'm exaggerating - you can see many of their posts on the KMPH board - posting the same 'manipulation', 'buy out imminent', etc posts there - and I would assume SRNE.
  • K
    Kenseth_Matt_17
    Lowest volume day since December 2nd. Kind of in line with the rest of the market. It’s pretty slow out there compared to recent trading.
  • T
    The Chief
    Pursuant to Standing Order ¶¶ 126.2 and 126.4, Senior Party, Lipocine, Inc., hereby
    2 notifies the Board that counsels for both parties had a conference call on April 5, 2021 and
    3 “discussion was had and that a good faith effort has been made to settle the contested case” but
    4 no settlement agreement was reached. Furthermore, pursuant to Standing Order ¶ 126.3, the
    5 parties have tentatively scheduled a further discussion for April 19, 2021.
  • C
    Chips
    Short Volume (not interest) on 3/30 was 62% on 4/9 was all the down to 21% That's a good sign to me.
    Bullish
  • 0
    082397
    Trading pattern is so weird. Bots trading to themselves and capping at certain points. Not normal human trading for sure. Sabby can go to h-e-double hockey sticks! Oh well, news soon enough. Have a great weekend fellow longs! Shorts can get a bad case of sand fleas in their own shorts.
  • D
    David
    I am sitting on 343,000 "Nay" Votes. I won't consider an alternative unless Management shares a coherent Business Plan consistent with the need to raise cash. No transparency, no check.
  • 0
    082397
    Totally controlled.........Lets get some prelim data on Fibrosis!!!!!!!
  • j
    jeff
    Someone wants cheap shares. This week I believe we hear Patel’s plan to partner
  • I
    IAN
    Regarding the recent 'settlement discussion'. If you go to the original source, you sill see that this is the case Clarus filed against LPCN in January (Jan 4, 2021). It does not seem to have anything to do with the court case LPCN has against Clarus (which is in federal district court - if I'm not mistaken).

    Clarus filed a case of interference with the PTAB on Jan 4, 2021 against Lipocine. That same day, the 'Standing orders' referenced by 'The Chief' were posted. You can easily go down and read the orders in paragraph 126 - which require 1) a settlement discussion to occur within a certain number of months of the opening of the case 2) the requirement that an announcement that (which is what "the chief" posted) the settlement conference occurred, and 3) that further settlement discussions can be scheduled. I'm not a lawyer so - you can all do your own DD, but This to my reading has absolutely nothing to do with the Federal case or a settlement discussion of that case (though of course - I would guess that everything is somewhat related internally). The April meeting was required by the PTAB, the report was required by the PTAB. But - IMHO there seems to be a fundamental misunderstanding here - about what this is.

    PS - you can read all of the documents here: https://acts.uspto.gov/ifiling/PublicView.jsp?identifier=106128&identifier2=null&tabSel=4&action=filecontent&replyTo=PublicView.jsp#
    Patent Trial and Appeal Board (PTAB)
    acts.uspto.gov
  • J
    Jeremy
    Very strange trading last 15 minutes or so, with no shares traded then a few then nothing... This stock just feels like someone is accumulating for past month or better while keeping the share price down. I hope we do get some crazy news that sends this soaring over 2.50 plus!
  • D
    David
    If Patel did not dilute or threaten to dilute or speak or write about possible dilution, or mention offering, or mention possible offering resulting in possible issue of shares, or something related, every 3 months, or more often, then this stock would already be at $3. But no, he has to dilute after each piece of good news, sometimes not allowing good news to sit for a week, sometimes not even 24 hours. Hey, sometimes he talks about dilution even ahead of good news. He wastes no time.
  • T
    Tony
    Looks like Clarus bs is coming to a head, maybe? Will be so happy to see them gone. I believe they have shot their wad. With LPCN’s science which is why I am invested may now manifest. Exciting times on the horizon.
  • E
    Edmund
    Wasn't today the day Lipocine was suppose to have another talk with Clarus?
  • I
    IAN
    Some weekend reading. For those who claim that 'all TRT is the same with regards to NASH' - take a look at Patent 16/517533. (Oh - LPCN is the owner). Here is a teaser:
    "For example, Huang et al. (PMID: 23292288) concluded "Testosterone administration in older men with mobility limitation and low testosterone levels was not associated with a reduction in hepatic fat." Moreover, elevated testosterone levels in females can associated with fatty liver, liver disease and related comorbidities. Magnussen et al PMID: 28522646 reported "hepatic fat content and VAT were unchanged" in males with type 2 diabetes and low testosterone levels that were treated for 24-weeks with a testosterone gel. Sattler et al PMID: 25392748 also reported that testosterone replacement did not have an effect of liver fat in 20 men with lower baseline levels of testosterone when treated for 20 weeks with a testosterone gel."

    "It was surprisingly discovered that oral testosterone (or androgen) therapy e.g., oral administration of a pharmaceutical composition containing a testosterone ester (e.g., or an androgen receptor agonist or anabolic agent), is particularly useful for treating liver disease. For example, it was found that the instant methods and compositions reduce relevant biomarker levels in patients having elevated biomarkers related to liver disease (e.g., fatty liver disease, liver fibrosis, alcoholic liver disease, hepatitis, steatosis, NAFLD, NASH, NASH with cirrhosis, and comorbidities of testosterone deficiency). "

    So - someone - explain to me why MD's would prescribe a generic testosterone gel - (which has been shown to be ineffective) - as compared to an oral agent? Then explain how other Oral TRT makers will 'treat NASH' - when LPCN owns a patent for: "A method of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, said method comprising orally administering to a subject a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof."